Greater Manchester kept running without Palantir's NHS platform. That is now a procurement fact.

NHS Greater Manchester's health care board has repeatedly declined to adopt the Palantir-built Federated Data Platform, sticking with a system it has built over the best part of a decade ^[9]. That refusal now sits inside a live commercial decision: the UK government has six months to decide whether to terminate a deal worth more than $400 million with Palantir ^[1], with a February opportunity to end the contract early rather than let it run to 2031 ^[15].

The platform was commissioned in 2023 ^[2] and began rolling out in early 2024 ^[3]. It pairs a national pool of health data with local databases that regions use for their own analyses and tools, such as waitlist management or discharge planning, all sitting on the same technical scaffolding so that something built in one place can in theory be picked up in another ^[5]. "You can lift and shift. That's the real power of the FDP," says Tom Bartlett, an independent consultant who previously ran the national rollout as deputy director of data engineering at NHS England ^[6]. The problem it addresses is real: NHS staff have tracked patients across digital systems, spreadsheets, paper and whiteboards, records have been left behind when patients move between care settings with occasionally deadly consequences, and funding decisions have been made on an incomplete patchwork ^[18]. Palantir and the NHS say the platform is already cutting wait times and hospital stays and improving use of operating theatres ^[4], and the Department of Health and Social Care says "thousands more patients are benefitting from the FDP every month" ^[8].

Adoption looks close to universal at the commissioning layer. NHS figures put 139 of roughly 200 trusts live and 35 of England's 36 integrated care boards actively using the system ^[7], which leaves about 61 trusts, near 30 percent, not live ^[19] and exactly one ICB outside ^[20]. Greater Manchester's board is the one that says it has repeatedly declined, arguing its own platform is functionally superior and more trusted by the public ^[9]. "Even a technically strong platform will struggle to realize value if clinicians, data controllers, patients or the public do not trust it," Matt Hennessey, its chief data and analytics officer, told WIRED, adding that full adoption "would be a retrograde step" ^[10][11].

That assessment is contested. Palantir and other advocates dispute it ^[12]. Andy Haywood of Health Innovation Manchester claims local trusts are counted as users without committing their data: "On the spreadsheet they go down as using it, but not in the sense of putting all their data in it" ^[13]. Palantir says Greater Manchester trusts use the platform extensively ^[14].

The precedent matters regardless of who is right about Manchester's numbers. A region opted out of a mandated national consolidation and continued to operate, which is the evidence any buyer lacks when a single vendor argues that partial adoption is not viable. The political context is separate but pushing the same way: Palantir's work in war and in the US immigration crackdown has drawn protests, petitions, parliamentary inquiries and a reported rebellion among NHS staff ^[16], and other European governments are reassessing their exposure to US-made technology ^[17].

Watch February. Ending the contract there would forgo roughly five years of a term running to 2031 ^[21], and the government's justification will rest on whether it treats one region's alternative as a workable model or an outlier.